Nicotinic Agonist and Cannabinoid Combination for Smoking Cessation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current tobacco and smokeless products fail to replicate the sensory experience of smoking tobacco, leading to unsatisfactory smoking cessation rates and emotional side effects from existing treatments.

Innovation Solution

A combination of a nicotinic agonist and a non-psychoactive cannabinoid, such as cannabidiol, administered through transdermal patches to provide a sensation similar to nicotine and reduce smoking cravings, respectively, in a controlled and tolerable dose.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If e-cigarettes or vaporizers are used to replace smoking tobacco, then health-related negative side-effects are reduced, but the sensation equivalent to smoking tobacco is not provided

Engineering Contradiction:

Improvehealth-related negative side-effectsVSAvoidsensation equivalent to smoking

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The patent combines two previously separate approaches (e-cigarette vaporization and cannabinoid therapy) into a single integrated system. The vaporizer delivers both nicotine-containing vapor and cannabinoid-containing vapor simultaneously, merging the harmful-reduction benefit of vaporization with the craving-reduction benefit of cannabinoids.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention uses composite vapor formulations containing both nicotine and cannabinoid compounds. These composite vapor mixtures provide the dual function of delivering nicotine for sensation while incorporating cannabinoids to reduce cravings and withdrawal symptoms, creating a more complete replacement experience.

Inventive Principle:

Principle #40Composite materials

2Reliability

If cannabinoid CB1 receptor antagonists like Rimonabant are used to treat nicotine dependence, then smoking cessation efficacy is improved, but emotional side effects such as nausea, anxiety and depression occur

Engineering Contradiction:

Improvesmoking cessation efficacyVSAvoidemotional side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Instead of using CB1 receptor antagonists (which block cannabinoid receptors and cause side effects), the invention uses CB1 receptor agonists or modulators. This inverted approach activates or modulates the same receptor system in a beneficial manner, reducing cravings and withdrawal symptoms without producing the harmful emotional side effects of antagonism.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The invention converts the previously harmful or neutral cannabinoid system into a therapeutic benefit. By utilizing the endocannabinoid system's natural role in reward and craving regulation, the patent transforms what could be a source of side effects (CB1 manipulation) into a mechanism that reduces withdrawal symptoms and supports cessation.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Quantity of substance

If nicotine replacement therapy is used to treat smoking addiction, then nicotine deficiency is addressed, but emotional cravings and sensation equivalent to smoking are not satisfied

Engineering Contradiction:

Improvenicotine replacementVSAvoidemotional cravings and sensation

Core Design Contradiction:

Quantity of substanceVSEase of operation

Solution Approach 1:

The patent merges nicotine replacement therapy with cannabinoid therapy in a single vaporization system. This combination addresses both the physiological nicotine deficiency and the psychological/emotional cravings simultaneously, providing a more complete treatment than nicotine replacement alone.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The vaporizer system performs multiple functions: it delivers nicotine for physiological replacement, provides vapor inhalation for sensory satisfaction, and administers cannabinoids for craving reduction. This multi-functional approach makes the device universally effective for both physical and psychological aspects of addiction.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP3595662B1Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction

Publication Date: 2023.07.12 PHARMA UNLTD BV

Figure 1

AI summary

A tobacco and smoke-less product comprises a first quantity of a first compound in a form suitable to release in-vivo in a human body a dose of a nicotinic agonist tolerable by the human body and sufficient to provide a sensation similar to that of nicotine released into the body by smoking tobacco. The product further comprises a second quantity of a second compound in a form suitable to release in-vivo in the human body a dose of non-psychoactive cannabinoid tolerable by the human body which reduces the desire to smoke tobacco. The product can be e.g. an epicurean product or a medical product, e.g. to treat smoking addition. The product can be provided in a kit of two or more products, such as to release different doses of the nicotinic agonist.